G01N 2333/9726
Tissue plasminogen activator
G01N2333/9726 (Tissue plasminogen activator) appears on 131 US grants and 43 published applications in this corpus.
Search patents in G01N- Granted patents
- 131
- Published applications
- 43
- Assignees
- 46
- Inventors
- 143
- Latest grant
- 17 Apr 2012
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 6 | 0 |
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 5 | 0 |
| 1996 | 8 | 0 |
| 1997 | 22 | 0 |
| 1998 | 27 | 0 |
| 1999 | 7 | 0 |
| 2000 | 9 | 0 |
| 2001 | 8 | 0 |
| 2002 | 6 | 5 |
| 2003 | 3 | 12 |
| 2004 | 5 | 6 |
| 2005 | 2 | 4 |
| 2006 | 2 | 4 |
| 2007 | 1 | 1 |
| 2008 | 3 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 1 | 1 |
| 2012 | 1 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity17 Apr 2012US 8,158,585 B2Crossbeta Biosciences B.V.
- Nucleic acid ligand complexes6 Dec 2011US 8,071,737 B2Glead Sciences, Inc.
- High affinity nucleic acid ligands to lectins15 Jul 2008US 7,399,752 B2Gilead Science, Inc.
- Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein20 May 2008US 7,375,076 B2The Regents of the University of Michigan
- Methods of producing nucleic acid ligands6 May 2008US 7,368,236 B2Gilead Sciences, Inc.
- Reporter labeled annular clot system for diagnosis and research10 Oct 2024US 2024/0337669 A1Indiana University Research and Technology Corporation
- Assessment of the risk of complication in a patient suspected of having an infection, having a sofa score lower than two3 Jun 2021US 2021/0165003 A1Biomerieux
- Apparatus and method for early identification of tpa resistance for clot dissolution in patients1 Mar 2018US 2018/0059124 A1
- Method for predicting treatment response and test for safe use of mesenchymal stem cells on inflammatory diseases9 Jun 2016US 2016/0161504 A1FundacióN PúBlica Andaluza Progreso Y Salud
- Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator24 Jan 2013US 2013/0022611 A1Genentech, Inc.
Most cited
By later US patents
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- Systematic evolution of ligands by exponential enrichment: Solution SELEX337US 5,567,588 AUniversity Research Corporation · 1996
- Systematic evolution of ligands by exponential enrichment: chimeric selex281US 5,637,459 ANeXstar Pharmaceuticals, Inc. · 1997
- High-affinity nucleic acid ligands that discriminate between theophylline and caffeine277US 5,580,737 ANeXstar Pharmaceuticals, Inc. · 1996
- Systematic evolution of ligands by exponential enrichment: blended SELEX233US 5,683,867 ANeXstar Pharmaceuticals, Inc. · 1997